Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
17 abstracts 1 to be shared, spanning a wide range of different cancer types, therapies and clinical study and real-world evidence designs Presentations will feature promising data across multiple cancers, including renal cell carcinoma, small cell lung cancer, pancreatic ductal ad...
Seven presentations represent Ipsen’s largest presence to date at ASBMR, the world’s leading scientific organization for bone health research Ipsen’s data demonstrate potential advances in understanding fibrodysplasia ossificans progressiva (FOP), including key lea...
IPSEN ( OTCPK:IPSEY ) discloses a share buyback of 11,614 shares between August 31 and September 4. More news on: Ipsen S.A., , Read more ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Economic reports in the week ahead The tech sector will be in focus again in the week ahead as investors gauge if short-term pandemic p...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Crinetics Pharmaceuticals (NASDAQ: CRNX ) announces that a presentation of its orally available small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session a the virtual European Congress of Endocrinology on September 8. More news on: Crinetics...
Crinetics Pharmaceuticals ( CRNX ) has a lead molecule, paltusotine, that may be best in class. Phase 2 testing is on track to be completed in Q4 2020 and may act as a catalyst for the stock to move up if the data is positive. Peak sales potential for paltusotine, if approved, could reach $1.5...
IPSEN ( OTCPK:IPSEY ) discloses a share buyback of 11,614 shares between August 17 and August 21. More news on: Ipsen S.A., Read more ...
Post hoc analyses showed substantial reduction (62%) in mean annualized new heterotopic ossification volume in patients with FOP who were treated with oral investigational therapy palovarotene 1 Results from the third interim analysis of the MOVE trial, the first and only multicenter ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2020. Resilient H1 financial performance : Group sales growth of 3.1% as reported and at constant currency, driven by...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...